The first-line effect of bortezomib-based therapy on clinical outcomes for Taiwanese patients with multiple myeloma

被引：0
|
作者：
Ho, C-L. [1 ]
Chen, J-H. [1 ]
机构：
[1] Triserv Gen Hosp, Natl Def Med Ctr, Dept Med, Taipei, Taiwan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1087P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical outcomes of bortezomib-based therapy in myeloma
    Djebbari, Faouzi
    Srinivasan, Anandagopal
    Valiance, Grant
    Moore, Sally
    Kothari, Jaime
    Ramasamy, Karthik
    PLOS ONE, 2018, 13 (12):
  • [2] BORTEZOMIB-BASED REGIMENS AS FIRST-LINE OR SALVAGE THERAPY FOR POEMS PATIENTS
    Riva, M.
    Lessi, F.
    Berno, T.
    Visentin, A.
    Campagnolo, M.
    Briani, C.
    Adami, F.
    HAEMATOLOGICA, 2017, 102 : 135 - 136
  • [3] BORTEZOMIB-BASED THERAPY IN FRAIL MULTIPLE MYELOMA PATIENTS
    Antonioli, E.
    Staderini, M.
    Nozzoli, C.
    Bacchiarri, F.
    Barone, F.
    Grieco, P.
    Coltro, G.
    Guarrera, A.
    Messeri, M.
    Bosi, A.
    HAEMATOLOGICA, 2017, 102 : 132 - 132
  • [4] Bortezomib-Based Triplet Therapy As First Line Treatment in Newly Diagnosed Multiple Myeloma Patients in Peru
    Vasquez, Jule F.
    Cordova, Naty Lopez
    Castillo, Claudia
    Saavedra, Alexandra
    Calle, Cindy
    Chavez, Lourdes Isabel Lopez
    Alcarraz, Cindy Elizabeth
    Rios, Pedro Eduardo Lovato
    Matuk, Alexandra La Torre
    Laboriano, Jorge
    Vilcarano, Abner
    Tokumura, Carmen
    Quintana, Shirley
    Samanez-Figari, Cesar
    Vidaurre, Tatiana
    BLOOD, 2024, 144 : 6997 - 6998
  • [5] Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis
    Liu, Wei-Nung
    Chang, Chao-Feng
    Chung, Chi-Hsiang
    Chien, Wu-Chien
    Huang, Tzu-Chuan
    Wu, Yi-Ying
    Ho, Ching-Liang
    Chen, Jia-Hong
    PLOS ONE, 2019, 14 (09):
  • [6] EFFICACY AND SAFETY OF BORTEZOMIB-BASED RETREATMENT IN MULTIPLE MYELOMA (MM) PATIENTS RELAPSING AFTER BORTEZOMIB-CONTAINING FIRST-LINE THERAPY: A RETROSPECTIVE STUDY
    Oriol, A.
    Giraldo, P.
    Kotsianidis, I.
    Couturier, C.
    Angermund, R.
    Broer, E.
    Corso, A.
    HAEMATOLOGICA, 2012, 97 : 609 - 610
  • [7] First-line bortezomib benefits patients with multiple myeloma
    Meletios A. Dimopoulos
    Evangelos Terpos
    Nature Reviews Clinical Oncology, 2009, 6 : 683 - 685
  • [8] REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB-BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?
    Demirsoy, Esra Terzi
    Geduk, Ayfer
    TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, 2022, 25 (01): : 58 - 67
  • [9] A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma
    Jagannath, S
    Brian, D
    Wolf, JL
    Camacho, E
    Irwin, D
    Lutzky, J
    McKinley, M
    Gabayan, E
    Mazumder, A
    Crowley, J
    Schenkein, D
    BLOOD, 2004, 104 (11) : 98A - 99A
  • [10] Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma
    Kortuem, Martin
    Einsele, Hermann
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (10) : 1661 - 1663
12345